Inhibition of mitochondrial translocase SLC25A5 and histone deacetylation is an effective combination therapy in neuroblastoma

The mitochondrion is a gatekeeper of apoptotic processes, and mediates drug resistance to several chemotherapy agents used to treat cancer. Neuroblastoma is a common solid cancer in young children with poor clinical outcomes following conventional chemotherapy. We sought druggable mitochondrial protein targets in neuroblastoma cells. Among mitochondria‐associated gene targets, we found that high expression of the mitochondrial adenine nucleotide translocase 2 (SLC25A5/ANT2), was a strong predictor of poor neuroblastoma patient prognosis and contributed to a more malignant phenotype in pre‐clinical models. Inhibiting this transporter with PENAO reduced cell viability in a panel of neuroblastoma cell lines in a TP53‐status‐dependant manner. We identified the histone deacetylase inhibitor, suberanilohydroxamic acid (SAHA), as the most effective drug in clinical use against mutant TP53 neuroblastoma cells. SAHA and PENAO synergistically reduced cell viability, and induced apoptosis, in neuroblastoma cells independent of TP53‐status. The SAHA and PENAO drug combination significantly delayed tumour progression in pre‐clinical neuroblastoma mouse models, suggesting that these clinically advanced inhibitors may be effective in treating the disease.

[1]  S. Hart,et al.  Silencing E3 Ubiqutin ligase ITCH as a potential therapy to enhance chemotherapy efficacy in p53 mutant neuroblastoma cells , 2020, Scientific Reports.

[2]  M. Fischer,et al.  A novel MYCN-specific antigene oligonucleotide deregulates mitochondria and inhibits tumor growth in MYCN-amplified Neuroblastoma. , 2019, Cancer research.

[3]  S. Groshen,et al.  Phase I study of vorinostat in combination with isotretinoin in patients with refractory/recurrent neuroblastoma: A new approaches to Neuroblastoma Therapy (NANT) trial , 2018, Pediatric blood & cancer.

[4]  Michael C. Heinold,et al.  The landscape of genomic alterations across childhood cancers , 2018, Nature.

[5]  Xin Zhou,et al.  Pan-cancer genome and transcriptome analyses of 1,699 pediatric leukemias and solid tumors , 2018, Nature.

[6]  P. Hogg,et al.  Dual targeting of mitochondrial function and mTOR pathway as a therapeutic strategy for diffuse intrinsic pontine glioma , 2018, Oncotarget.

[7]  Arnold J Levine,et al.  Why are there hotspot mutations in the TP53 gene in human cancers? , 2017, Cell Death and Differentiation.

[8]  F. Sotgia,et al.  Mitochondrial mRNA transcripts predict overall survival, tumor recurrence and progression in serous ovarian cancer: Companion diagnostics for cancer therapy , 2017, Oncotarget.

[9]  C. Sander,et al.  Mitochondrial respiratory gene expression is suppressed in many cancers , 2016, eLife.

[10]  D. Stolz,et al.  N-Myc overexpression increases cisplatin resistance in neuroblastoma via deregulation of mitochondrial dynamics , 2016, Cell Death Discovery.

[11]  J. Desai,et al.  First-in-man trial of 4-(N-(S-penicillaminylacetyl)amino) phenylarsonous acid (PENAO) as a continuous intravenous infusion (CIVI), in patients (pt) with advanced solid tumours. , 2016 .

[12]  R. Versteeg,et al.  High efficacy of the BCL-2 inhibitor ABT199 (venetoclax) in BCL-2 high-expressing neuroblastoma cell lines and xenografts and rational for combination with MCL-1 inhibition , 2016, Oncotarget.

[13]  Y. Jeon,et al.  Targeting Adenine Nucleotide Translocase-2 (ANT2) to Overcome Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor in Non–Small Cell Lung Cancer , 2016, Molecular Cancer Therapeutics.

[14]  U. Hellman,et al.  The 1p36 Tumor Suppressor KIF 1Bβ Is Required for Calcineurin Activation, Controlling Mitochondrial Fission and Apoptosis. , 2016, Developmental cell.

[15]  Gudrun Schleiermacher,et al.  Advances in Risk Classification and Treatment Strategies for Neuroblastoma. , 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[16]  S. Groshen,et al.  Phase I Study of Vorinostat as a Radiation Sensitizer with 131I-Metaiodobenzylguanidine (131I-MIBG) for Patients with Relapsed or Refractory Neuroblastoma , 2015, Clinical Cancer Research.

[17]  K. Hess,et al.  Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[18]  P. Hogg,et al.  Dual-targeting of aberrant glucose metabolism in glioblastoma , 2015, Journal of experimental & clinical cancer research : CR.

[19]  S. Weinberg,et al.  Targeting mitochondria metabolism for cancer therapy. , 2015, Nature chemical biology.

[20]  Doo Sin Jo,et al.  Suppression of Cpn10 Increases Mitochondrial Fission and Dysfunction in Neuroblastoma Cells , 2014, PloS one.

[21]  A. Blackburn,et al.  Targeting of two aspects of metabolism in breast cancer treatment , 2014, Cancer biology & therapy.

[22]  Yanhong Zhang,et al.  Arsenic Trioxide Reactivates Proteasome-Dependent Degradation of Mutant p53 Protein in Cancer Cells in Part via Enhanced Expression of Pirh2 E3 Ligase , 2014, PloS one.

[23]  N. Ikegaki,et al.  Destabilization of MYC/MYCN by the mitochondrial inhibitors, metaiodobenzylguanidine, metformin and phenformin , 2013, International journal of molecular medicine.

[24]  A. Letai,et al.  Mitochondria: gatekeepers of response to chemotherapy. , 2013, Trends in cell biology.

[25]  J. Hagenbuchner,et al.  BIRC5/Survivin enhances aerobic glycolysis and drug resistance by altered regulation of the mitochondrial fusion/fission machinery , 2013, Oncogene.

[26]  Steven J. M. Jones,et al.  The genetic landscape of high-risk neuroblastoma , 2013, Nature Genetics.

[27]  M. Bottone,et al.  Mitochondrial fusion: a mechanism of cisplatin-induced resistance in neuroblastoma cells? , 2013, Neurotoxicology.

[28]  S. Nilsson,et al.  Tumor Development, Growth Characteristics and Spectrum of Genetic Aberrations in the TH-MYCN Mouse Model of Neuroblastoma , 2012, PloS one.

[29]  M. Hogarty,et al.  Molecular and Cellular Pathobiology Mitochondrial Bcl-2 Family Dynamics Define Therapy Response and Resistance in Neuroblastoma , 2022 .

[30]  P. Hogg,et al.  The tumour metabolism inhibitors GSAO and PENAO react with cysteines 57 and 257 of mitochondrial adenine nucleotide translocase , 2012, Cancer Cell International.

[31]  U. Moll,et al.  SAHA shows preferential cytotoxicity in mutant p53 cancer cells by destabilizing mutant p53 through inhibition of the HDAC6-Hsp90 chaperone axis , 2011, Cell Death and Differentiation.

[32]  W. Miller,et al.  Vorinostat Induces Reactive Oxygen Species and DNA Damage in Acute Myeloid Leukemia Cells , 2011, PloS one.

[33]  P. Reynier,et al.  Adenine nucleotide translocase 2 is a key mitochondrial protein in cancer metabolism. , 2011, Biochimica et biophysica acta.

[34]  F. Talos,et al.  Functional Inactivation of Endogenous MDM2 and CHIP by HSP90 Causes Aberrant Stabilization of Mutant p53 in Human Cancer Cells , 2011, Molecular Cancer Research.

[35]  Seong-Jun Cho,et al.  Mutant p53 Protein Is Targeted by Arsenic for Degradation and Plays a Role in Arsenic-mediated Growth Suppression* , 2011, The Journal of Biological Chemistry.

[36]  S. Pervaiz,et al.  Adenine nucleotide translocase family: four isoforms for apoptosis modulation in cancer , 2011, Oncogene.

[37]  L. Galluzzi,et al.  Targeting mitochondria for cancer therapy , 2010, Nature Reviews Drug Discovery.

[38]  M. Cole,et al.  High Frequency of p53/MDM2/p14ARF Pathway Abnormalities in Relapsed Neuroblastoma , 2010, Clinical Cancer Research.

[39]  P. Hogg,et al.  Optimization of the antitumor efficacy of a synthetic mitochondrial toxin by increasing the residence time in the cytosol. , 2009, Journal of medicinal chemistry.

[40]  A. Gudkov,et al.  p53 determines multidrug sensitivity of childhood neuroblastoma. , 2007, Cancer research.

[41]  E. May,et al.  Expression of C-terminal deleted p53 isoforms in neuroblastoma , 2006, Nucleic acids research.

[42]  U. Kees,et al.  Increased frequency of aberrations in the p53/MDM2/p14(ARF) pathway in neuroblastoma cell lines established at relapse. , 2006, Cancer research.

[43]  B. Chabi,et al.  ANT2 Isoform Required for Cancer Cell Glycolysis , 2005, Journal of bioenergetics and biomembranes.

[44]  J. Folkman,et al.  A peptide trivalent arsenical inhibits tumor angiogenesis by perturbing mitochondrial function in angiogenic endothelial cells. , 2003, Cancer cell.

[45]  Petr Pancoska,et al.  p53 has a direct apoptogenic role at the mitochondria. , 2003, Molecular cell.

[46]  D. Bernhard,et al.  The histone deacetylase inhibitor and chemotherapeutic agent suberoylanilide hydroxamic acid (SAHA) induces a cell-death pathway characterized by cleavage of Bid and production of reactive oxygen species , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[47]  G. Mohapatra,et al.  Targeted expression of MYCN causes neuroblastoma in transgenic mice , 1997, The EMBO journal.

[48]  Hu Shih,et al.  Development of Methodology , 1980 .

[49]  M. Wood,et al.  Analysis and interpretation of data. , 1978, The Journal of family practice.